Izdean Mufleh
Internal Medicine · Boca Raton, FLNPI 1053707604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,570 of the $2,441 with a category attached, or 64.3%. 18 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 55.7% of the total. Reporting peaked in 2023 at $1,410 and has fallen 76.7% since, to $329 in 2025.
Across 61 payments — averaging $40.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Lilly USA, LLC$203
- Abbott$128
- Boehringer Ingelheim$128
- Novo Nordisk$123
- Bayer$89
- plus $409 from 12 others
Across 111 payments — averaging $4758.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$505K
- Boehringer Ingelheim International GmbH$23K
What the payments were for
- Travel & lodging$87136%
- Food & beverage$1,57064%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,361 |
| Lilly USA, LLC | 10 | $203 |
| Abbott | 3 | $128 |
| Boehringer Ingelheim | 6 | $128 |
| Novo Nordisk | 7 | $123 |
| Bayer | 3 | $89 |
| Astellas Pharma US Inc | 3 | $54 |
| Pfizer | 4 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Eli Lilly | 1 | $51 |
| Amneal Pharmaceuticals LLC | 3 | $40 |
| Neuronetics, Inc. | 1 | $35 |
| Exact Sciences | 1 | $28 |
| Merck | 2 | $23 |
| Johnson & Johnson | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Companion Medical, Inc. | 1 | $17 |
How this compares
$2,441 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $44,396 |
| MounjaroTirzepatide | 22 | $32,403 |
| EliquisApixaban | 16 | $22,620 |
| JardianceEmpagliflozin | 15 | $20,968 |
| Repatha SureclickEvolocumab | 13 | $12,318 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $2,008 |
| Rosuvastatin Calcium | 78 | $1,317 |
| Atorvastatin Calcium | 114 | $1,205 |
| Testosterone Cypionate | 28 | $1,005 |
| Amlodipine Besylate | 107 | $809 |
| Losartan Potassium | 83 | $775 |
| Gabapentin | 33 | $663 |
| Levothyroxine Sodium | 78 | $663 |
| Pantoprazole Sodium | 61 | $526 |
| Tamsulosin Hcl | 26 | $501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $123 | $44,39642 claims |
| Lilly USA, LLCMounjaro | $203 | $32,40322 claims |
| PfizerEliquis | $52 | $22,62016 claims |
| Boehringer IngelheimJardiance | $128 | $20,96815 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $66378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Boca Raton
- Richard MarquesBoca Raton$42K
- Viraj ShahBoca Raton$37K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.